Vita 34 AG
XMUN:V3V
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
V
|
Vita 34 AG
XMUN:V3V
|
DE |
|
Vyne Therapeutics Inc
NASDAQ:VYNE
|
US |
|
Ebix Inc
OTC:EBIXQ
|
US |
|
Universal Insurance Holdings Inc
F:5UI
|
US |
|
S
|
State Bank of India
F:SID
|
IN |
|
C
|
CNOOC Ltd
F:NC2B
|
CN |
|
S
|
Sinopharm Group Co Ltd
F:X2S
|
CN |
|
Edgio Inc
NASDAQ:EGIO
|
US |
|
D
|
Deutsche Post AG
XMUN:DHL
|
DE |
|
HashiCorp Inc
F:YR8
|
US |
|
H
|
Hexagon Purus ASA
XMUN:0QJ
|
NO |
|
Garrett Motion Inc
NASDAQ:GTX
|
CH |
|
B
|
Beiersdorf AG
DUS:BEI
|
DE |
Wall St Price Targets
V3V Price Targets Summary
Vita 34 AG
According to Wall Street analysts, the average 1-year price target for V3V is 7.69 EUR with a low forecast of 7.62 EUR and a high forecast of 7.92 EUR.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is V3V's stock price target?
Price Target
7.69
EUR
According to Wall Street analysts, the average 1-year price target for V3V is 7.69 EUR with a low forecast of 7.62 EUR and a high forecast of 7.92 EUR.
What is the Revenue forecast for Vita 34 AG?
Projected CAGR
4%
Over the last 13 years, the compound annual growth rate for Revenue has been 12%. The projected CAGR for the next 9 years is 4%.
What is the Gross Profit forecast for Vita 34 AG?
Projected CAGR
10%
Over the last 13 years, the compound annual growth rate for Gross Profit has been 8%. The projected CAGR for the next 4 years is 10%.
